β-thalassemia

Hematology

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.

$3.6B marketMature→ Stable30 products15 companies

Key Trends

IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders

Career Verdict

Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	IMBRUVICA (ibrutinib)	AbbVie	$2.4B	65%	Peak	Stable	9.0yr
2	PROMACTA (eltrombopag olamine)	Novartis	$558M	15%	LOE Approaching	Declining	1.7yr
3	AURYXIA (ferric citrate)	Ipsen	$183M	5%	Peak	Stable	4.2yr
4	OXBRYTA (voxelotor)	Pfizer	$101M	3%	Peak	Growing	11.4yr
5	DOPTELET (avatrombopag maleate)	Unknown	$96M	3%	LOE Approaching	Declining	1.2yr

#1IMBRUVICA

$2.4B

AbbVie·Peak9.0yr

#2PROMACTA

$558M

Novartis·LOE Approaching1.7yr

#3AURYXIA

$183M

Ipsen·Peak4.2yr

#4OXBRYTA

$101M

Pfizer·Peak11.4yr

#5DOPTELET

$96M

Unknown·LOE Approaching1.2yr

Drug Class Breakdown

Protein Kinase Inhibitors

$2.4B(65%)

dominates market, stable

TPO-receptor agonists

$654M(18%)

multiple players, patent risk

Iron metabolism modulators

$183M(5%)

niche, CKD-focused

Hemoglobin polymerization inhibitors

$101M(3%)

sickle cell focused, growing

JAK2 inhibitors

$50M(1%)

myeloproliferative neoplasms, early growth

Erythropoiesis-stimulating agents

$60M(2%)

legacy class, biosimilar pressure

Leukocyte growth factors

$68M(2%)

biosimilar-saturated, mature

Career Outlook

Stable

Hematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.

Breaking In

Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.

For Experienced Professionals

Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).

In-Demand Skills

Managed care/payer strategyHematologic malignancy genetics (BTK, JAK2 mutations)TPO-receptor pharmacologyRare disease diagnosis and patient identificationBiosimilar/generic competitive strategyMedical writing for limited indication populations

Best For

Medical Science Liaison (rare disease focus)Brand Manager (specialty hematology)Managed Care DirectorClinical Operations ManagerPayer Strategy AnalystHealth Economics & Outcomes Research (HEOR) specialist

Hiring Landscape

$91K-$204K

Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.

102

Open Roles

Companies Hiring

Departments

Top Hiring Companies

By Department

Commercial(24%)

$201K

Clinical Operations(18%)

$91K

Medical Affairs(15%)

$204K

Manufacturing(7%)

$175K

R&D(7%)

$147K

Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

SandozAustria - Kundl

1 program

DeferasiroxPhase 1

Protagonist TherapeuticsAustralia - Brisbane

2 programs

PTG-300PHASE_21 trial

Active Trials

NCT03802201Completed63Est. Jul 2020

NCT04054921Completed34Est. Jul 2020

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Protagonist TherapeuticsPTG-300

Clinical Trials (2)

Total enrollment: 97 patients across 2 trials

NCT04054921 Protagonist TherapeuticsPTG-300

Safety Study for Beta Thalassemia Subjects on PTG-300

Start: May 2019Est. completion: Jul 202034 patients

Phase 2Completed

NCT03802201 Protagonist TherapeuticsPTG-300

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

Start: Dec 2018Est. completion: Jul 202063 patients

Phase 2Completed

Related Jobs in Hematology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Anemia(259)Myelofibrosis(78)Aplastic Anemia(40)Polycythemia Vera(40)Primary Myelofibrosis(31)Thrombocytopenia(31)Iron Deficiency Anemia(26)Immune Thrombocytopenia(26)Primary Immune Thrombocytopenia(24)Beta-Thalassemia(23)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.